Recurrent Rectal Cancer Terminated Phase 0 Trials for Dasatinib (DB01254)

Also known as: Rectal cancer recurrent / Carcinoma rectum recurrent / Rectal carcinoma recurrent / Carcinoma of rectum recurrent

IndicationStatusPhase
DBCOND0028583 (Recurrent Rectal Cancer)Terminated0
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00835679Cetuximab and/or Dasatinib in Patients With Colorectal Cancer and Liver Metastases That Can Be Removed by SurgeryBasic Science